We are live on ! Find out more
VIGL

Vigil Neuroscience

Delisted

VIGL was delisted on the 4th of August, 2025.

35 hedge funds and large institutions have $43.7M invested in Vigil Neuroscience in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1.83% less ownership

Funds ownership: 63.18%61.35% (-1.8%)

26% less funds holding

Funds holding: 4735 (-12)

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

65% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 17

65% less capital invested

Capital invested by funds: $125M → $43.7M (-$81.4M)

Holders
35
Holders Change
-12
Holders Change %
-25.53%
% of All Funds
0.59%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
6
Increased
6
Reduced
13
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$15.1M
NV
2
Northpond Ventures
Maryland
$10.9M
Citadel Advisors
3
Citadel Advisors
Florida
$5.47M +$9.47K +2,397 +0.1%
AG
4
Artal Group
Luxembourg
$2.89M
CAM
5
Cormorant Asset Management
Massachusetts
$1.59M
PBPIA
6
Pivotal bioVenture Partners Investment Advisor
California
$1.45M
RSCM
7
Rock Springs Capital Management
Maryland
$1.22M
Vanguard Group
8
Vanguard Group
Pennsylvania
$914K -$122K -30,990 -8%
DTC
9
Deep Track Capital
Connecticut
$796K -$319K -80,748 -21%
HMC
10
Harvard Management Company
Massachusetts
$747K
LGM
11
Logos Global Management
California
$530K
LCM
12
Laurion Capital Management
New York
$336K +$514K +130,200 New
BlackRock
13
BlackRock
New York
$269K -$788K -199,466 -66%
Barclays
14
Barclays
United Kingdom
$262K -$4.31K -1,092 -1%
DCM
15
DAFNA Capital Management
California
$257K
Goldman Sachs
16
Goldman Sachs
New York
$189K -$3.01K -762 -1%
Citigroup
17
Citigroup
New York
$168K +$3.83K +969 +2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$153K -$148K -37,435 -39%
PI
19
PEAK6 Investments
Illinois
$135K +$56.6K +14,337 New
Renaissance Technologies
20
Renaissance Technologies
New York
$97K +$68.9K +17,447 +87%
LP
21
LMR Partners
United Kingdom
$65K -$9.1K -2,305 -8%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$57K +$88K +22,269 New
State Street
23
State Street
Massachusetts
$47K -$143K -36,105 -66%
Northern Trust
24
Northern Trust
Illinois
$31K -$176K -44,601 -79%
PHK
25
Point72 Hong Kong
Hong Kong
$31K -$2.08K -528 -4%

VIGL Hedge Fund Activity: Q2 2022 in Review

35 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q2 2022, worth a combined $43.7M — down 65% from $125M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of VIGL and 6 opened new positions — a net loss of 11 holders — while 13 trimmed existing stakes and 6 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $514K. The largest seller was BlackRock, cutting an estimated $788K.

  • 35 institutional investors held Vigil Neuroscience (VIGL) as of Q2 2022, down from 47 in Q1 2022.
  • Funds reported $43.7M of Vigil Neuroscience stock for Q2 2022, down 65% quarter-over-quarter.
  • 6 funds opened new Vigil Neuroscience positions in Q2 2022 and 17 closed out, a net change of -11 holders.
  • The largest Vigil Neuroscience buyer in Q2 2022 was Laurion Capital Management, an estimated $514K added.
  • The largest Vigil Neuroscience seller in Q2 2022 was BlackRock, an estimated $788K sold.

Based on aggregated 13F filings for Q2 2022.